Sweat-gland carcinoma with neuroendocrine differentiation (SCAND): a clinicopathologic study of 13 cases with genetic analysis

• DOI: 10.1038/s41379-021-00921-8
• Publication Date: 2021-09-13T08:04:29Z
• Authors: Keisuke Goto; Yoji Kukita; Keiichiro Honma; Nobuyuki Ohike; Takaya Komori; Yoshihiro Ishida; Misawo Ishikawa; Takashi Nakatsuka; Soichi Fumita; Koichi Nakagawa; Aya Okabayashi; Yoshifumi Iwahashi; Tomoyuki Tanino; Keisuke Kikuchi; Yoshie Kawahara; Tsunekazu Hishima; Jiro Uehara; Takuma Oishi; Taiki Isei
• Keywords: Adult; Aged, 80 and over; Male; Carcinoma; Middle Aged; Immunohistochemistry; Carcinoma, Neuroendocrine; 3. Good health; Sweat Gland Neoplasms; 03 medical and health sciences; 0302 clinical medicine; Lymphatic Metastasis; Humans; Female; Aged

Low-grade neuroendocrine carcinoma of the skin (LGNECS) was proposed in 2017 as a new primary cutaneous neoplasm with neuroendocrine differentiation; however, it is not yet well known due to its rarity. Herein, we perform a detailed clinicopathologic analysis of 13 cases as well as panel DNA sequencing in three cases. The study included 12 males and 1 female with a median age of 71 (43-85) years. All lesions occurred on the ventral trunk. The mean tumor size was 2.2 (0.8-11.0) cm. The histopathology resembled that of well-differentiated neuroendocrine tumors (NETs) in other organs, but intraepidermal pagetoid spreading was seen in 8 (61.5%) cases and stromal mucin deposits in 4 (30.8%). Immunoreactivity for CK7, CK19, EMA, BerEP4, CEA, chromogranin A, synaptophysin, INSM1, GCDFP15, GATA3, ER, and bcl-2 were present in varying degrees in all tested cases. PTEN c.165-1G>A splice site mutation was detected by panel sequencing in one case, and GATA3 P409fs*99 and SETD2 R1708fs*4 in another case. Lymph node metastasis was seen significantly in cases with tumor size >2.0 cm [8/8 (100%) vs. 1/5 (20%)]. All three cases with size >3.0 cm were in unresectable advanced-stage [3/3 (100%) vs. 1/10 (10%)], and two of the three patients succumbed to the disease. The two cases of death revealed mild nuclear atypia (mitosis: 1/10 HPFs) and moderate nuclear atypia (2/10 HPFs). Thus, tumor size would be a better prognostic factor than nuclear atypia, mitotic count, and Ki67 index, unlike in NETs. These clinicopathologic and immunohistochemical features would represent the characteristics as skin adnexal tumors with apocrine/eccrine differentiation rather than NETs; therefore, we rename it as sweat-gland carcinoma with neuroendocrine differentiation (SCAND).